This Article  • References  • Full text PDF  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Citation map  • Contact me when this article is cited  Related Content  • Similar articles in this journal  Social Bookmarking   What's this?

Leonard F. Ditmanson, MD; David A. Apgar, PharmD
Tucson, Ariz

Arch Intern Med. 1996;156(1):111-112.

	Since this article does not have an abstract, we have provided the first 150 words of the full text PDF and any section headings.

We would like to express an opinion about a recent publication in your journal concerning the use of short-course ciprofloxacin for the treatment of acute uncomplicated urinary tract infection in (otherwise healthy) women.¹ We question the use of any broadspectrum agent (including fluoroquinolones) for the treatment of this type of urinary tract infection. We submit that the real value of the fluoroquinolone antibiotics is still as unique oral agents for the treatment of resistant gram-negative bacillary infections when their use clearly decreases hospitalization time or the need for intravenous therapy.

We are currently experiencing a global problem of increasing resistance to microorganisms, some of which are becoming a major concern in the United States (eg, penicillin-resistant Streptococcus pneumoniae, multidrugresistant Mycobacterium tuberculosis, methicillinresistant Staphylococcus aureus, and vancomycinresistant enterococci). The American Medical Association has acknowledged this problem to the extent that it has announced that its 10 affiliated journals will feature . . . [Full Text PDF of this Article]

CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter     What's this?